Homepage Top Section 1

Claimed to have high clinical potential to treat Covid-19, Silmitasertib acts on the protein kinase CK2 pathway. As a CK2-inhibitor, it is believed to hinder the active viral

Japan has approved AstraZeneca’s Forxiga (dapagliflozin) to treat chronic kidney disease (CKD) in adults with and without type-2 diabetes (T2D). The Japanese Ministry of Health, Labour and Welfare

This approval expands the total count of Covid-19 vaccines authorised in the country to five. Last week, J&J submitted an application seeking Emergency Use Authorization (EUA) for its

This vaccine candidate is based on the company’s Fc fusion protein platform. It stimulates a Th1/Th2 mixed immune response against the receptor-binding domain (RBD) of the SARS-CoV-2 spike

Moderna has announced plans to increase its global manufacturing capacity for Covid-19 vaccine by making additional capital investments. The investments will be made at the company’s owned and

Belgium-based biopharmaceutical firm UCB has expanded its collaboration with technology company Microsoft to accelerate discovery and development of drugs for people living with severe diseases in immunology and

GlaxoSmithKline has signed an agreement with Vir Biotechnology to expand their Covid-19 collaboration to advance new therapeutics for influenza and other respiratory viruses. The company stated that the

Swiss pharmaceutical company Novartis has secured the expanded US Food and Drug Administration (FDA) indication for Entresto, a Novartis therapy to treat patients diagnosed with guideline-defined heart failure.